Evidence method
Level · gp.fundamentals.capex_revenue_ratio
0.00% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
RKDA · Jun 30, 2025
Arcadia Biosciences, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000950170-25-109040General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-139.73% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
11.41% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
102.34% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
43.37% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-34.43% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
0.62% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
5.91% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History19 statesSelf-history eligible
Dec 31, 20210/7 normalizedLevel 3Mar 31, 20220/7 normalizedLevel 3Jun 30, 20220/7 normalizedLevel 3Sep 30, 20220/8 normalizedLevel 3Dec 31, 20220/8 normalizedLevel 3Mar 31, 20230/8 normalizedLevel 3Jun 30, 20230/8 normalizedLevel 3Sep 30, 20236/8 normalizedLevel 3Dec 31, 20237/8 normalizedLevel 3Mar 31, 20247/8 normalizedLevel 3Jun 30, 20247/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20266/6 normalizedLevel 3Jun 30, 20267/7 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- -132.33%
- Current
- -139.73%
- Delta
- -7.39%
- Previous
- -4.38%
- Current
- 11.41%
- Delta
- 15.79%
- Previous
- 107.08%
- Current
- 102.34%
- Delta
- -4.75%
- Previous
- 43.17%
- Current
- 43.37%
- Delta
- 0.20%
- Previous
- 44.17%
- Current
- -34.43%
- Delta
- -78.60%
- Previous
- 0.00%
- Current
- 0.62%
- Delta
- 0.62%
- Previous
- 6.50%
- Current
- 5.91%
- Delta
- -0.59%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · RKDA Fundamental State →Analogous To · RKDA state analogue 1 →Has State · Arcadia Biosciences, Inc. →Transitioned To · RKDA Fundamental State →Transitioned To · RKDA CASH_GENERATION_DECREASED →Transitioned To · RKDA GROWTH_INCREASED →Transitioned To · RKDA INVENTORY_PRESSURE_DECREASED →Transitioned To · RKDA MARGIN_INCREASED →Transitioned To · RKDA PROFITABILITY_DECREASED →Transitioned To · RKDA R_AND_D_INTENSITY_INCREASED →Transitioned To · RKDA SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.